0
Abstract: Poster Presentations |

PENETRATION OF AMPHOTERICIN B IN HUMAN LUNG TISSUE AFTER SINGLE LIPOSOMAL AMPHOTERICIN B INFUSION FREE TO VIEW

Cosimo Lequaglie, MD*; Franco Fraschini, PhD; Germana Demartini, PhD; Franco Scaglione, PhD
Author and Funding Information

Centro di Riferimento Oncologico Basilicata, Rionero in Vulture, Italy


Chest


Chest. 2005;128(4_MeetingAbstracts):373S. doi:10.1378/chest.128.4_MeetingAbstracts.373S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  To investigate the tissue levels and distribution of amphotericin B in lung after i.v. administration of liposomal amphotericin B (L-AmB) in patients with lung cancer resected.

METHODS:  We enrolled 18 adult (>18 ys) patients with primary or secondary lung cancers. All patients were informed about the prospective study. There were 12 males and 6 females, both sexes ranging in weight from 53 to 86 kg, and in age from 28 to 65 years. L-AmB was administered by 1 hour single infusion at fixed doses of 1,5 mg/kg, and it was administered from 10 to 25 hours before the surgery. The starting and the end points of infusion were noted, the same for arterial and vein ligatures, and the end point of pulmonary tissue sample collection. Moreover, 10 ml of blood sample at the artery closure were collected. L-AmB was assayed in blood and lung tissue by an HPLC validated method of Bekersky et all (Shimadzu LC-9A pump, SPD-6A detector, CR-4A data processor, Simmetry Shield RP8 water column).

RESULTS:  The blood levels after 10 to 16 hours from the end of infusion (n° 6) ranged from 3.4 to 2.1 mg/l-gr, while the tissue levels ranged from 0.9 to 1.59 mg/l-gr; 18 to 22 hours after blood infusion (n° 6) levels ranged from 1.8 to 0.9 mg/l-gr; 23 to 25 hours after infusion (n° 6) blood and the tissue levels ranged from 1.8 to 0.98 mg/l-gr and 1.48 to 2.38 mg/l-gr.

CONCLUSION:  These data support the consistent lung tissue diffusion of L-AmB in patients with lung cancers. The L-AmB plasma concentration was gradually decreasing in all the cases.

CLINICAL IMPLICATIONS:  The relationship between these data can effort the best choice of drug in possible fungal infections as for a prophylactic employment for lower dosage and for lower collateral side effects.

DISCLOSURE:  Cosimo Lequaglie, None.

Wednesday, November 2, 2005

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543